Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA ...

Retrieved on: 2024-09-19 20:45:58

Tags for this article:

Protein domains

B-cell maturation antigen

Regenerative Medicine Advanced Therapy

Multiple myeloma

CAR T cell

Serum B-cell maturation antigen

Poseida Therapeutics Inc.

Click the tags to see associated articles and topics

Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA .... View article details on hiswai:

Summary

Poseida Therapeutics' P-BCMA-ALLO1 CAR T-cell therapy has received RMAT designation for treating multiple myeloma. The therapy targets B-cell maturation antigen and uses advanced technology, aligning with key regenerative medicine principles.

Article found on: www.cgtlive.com

View Original Article